Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Current Deferred Revenue (2016 - 2022)

Myriad Genetics (MYGN) has disclosed Current Deferred Revenue for 12 consecutive years, with $200000.0 as the latest value for Q3 2022.

  • Quarterly Current Deferred Revenue fell 98.26% to $200000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $200000.0 through Sep 2022, down 98.26% year-over-year, with the annual reading at $5.2 million for FY2021, 84.1% down from the prior year.
  • Current Deferred Revenue for Q3 2022 was $200000.0 at Myriad Genetics, down from $300000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $32.8 million in Q2 2020, with the low at $200000.0 in Q3 2022.
  • Average Current Deferred Revenue over 5 years is $10.2 million, with a median of $2.6 million recorded in 2018.
  • The sharpest move saw Current Deferred Revenue skyrocketed 1438.1% in 2020, then plummeted 98.67% in 2022.
  • Over 5 years, Current Deferred Revenue stood at $2.4 million in 2018, then surged by 50.0% to $3.6 million in 2019, then surged by 808.33% to $32.7 million in 2020, then plummeted by 84.1% to $5.2 million in 2021, then crashed by 96.15% to $200000.0 in 2022.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $200000.0, $300000.0, and $700000.0 for Q3 2022, Q2 2022, and Q1 2022 respectively.